MicroRNA-1468 promotes tumor progression by activating PPAR-γ-mediated AKT signaling in human hepatocellular carcinoma
暂无分享,去创建一个
Wei Yang | Liang Wang | Qingguang Liu | Wei Yang | Qiuran Xu | Liang Wang | K. Tu | Qing Li | Zhikui Liu | Changwei Dou | Zhikui Liu | Yufeng Wang | Changwei Dou | Liankang Sun | Qing Li | Qiuran Xu | Kangsheng Tu | Yufeng Wang | Qingguang Liu | Liankang Sun
[1] Xin Zheng,et al. High‑mobility group box 1 has a prognostic role and contributes to epithelial mesenchymal transition in human hepatocellular carcinoma. , 2015, Molecular medicine reports.
[2] Meng Xu,et al. Methylation-mediated repression of microRNA-129-2 suppresses cell aggressiveness by inhibiting high mobility group box 1 in human hepatocellular carcinoma , 2016, Oncotarget.
[3] Wei Yang,et al. MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT signaling in hepatocellular carcinoma , 2015, International journal of oncology.
[4] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[5] Yu-qin Pan,et al. MicroRNA expression profiles predict progression and clinical outcome in lung adenocarcinoma , 2016, OncoTargets and therapy.
[6] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[7] A. Covey,et al. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma , 2012, CA: a cancer journal for clinicians.
[8] Krishna R. Kalari,et al. Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study , 2012, BMC Cancer.
[9] H. Koeffler. Peroxisome proliferator-activated receptor γ and cancers , 2003 .
[10] Zhongliang Zhu,et al. The human RNA surveillance factor Up-frameshift 1 inhibits hepatic cancer progression by targeting MRP2/ABCC2. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[11] David S. Park,et al. CITED2 Signals through Peroxisome Proliferator-Activated Receptor-γ to Regulate Death of Cortical Neurons after DNA Damage , 2008, The Journal of Neuroscience.
[12] E. Lam,et al. Cited2, a coactivator of HNF4α, is essential for liver development , 2007 .
[13] C. Grommes,et al. Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists , 2004 .
[14] Ming Shi,et al. Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.
[15] Helen C. Hurst,et al. Physical and Functional Interactions among AP-2 Transcription Factors, p300/CREB-binding Protein, and CITED2* , 2003, The Journal of Biological Chemistry.
[16] E. Lam,et al. Cited2, a coactivator of HNF4alpha, is essential for liver development. , 2007, EMBO Journal.
[17] Jie Sun,et al. MicroRNAs in Hepatocellular Carcinoma: Regulation, Function, and Clinical Implications , 2013, TheScientificWorldJournal.
[18] H. El‐Serag,et al. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.
[19] C. Weng,et al. Excavatolide B inhibits nonsmall cell lung cancer proliferation by altering peroxisome proliferator activated receptor gamma expression and PTEN/AKT/NF‐Kβ expression , 2017, Environmental toxicology.
[20] J. W. Davis,et al. Identification of the CREB-binding Protein/p300-interacting Protein CITED2 as a Peroxisome Proliferator-activated Receptor α Coregulator* , 2004, Journal of Biological Chemistry.
[21] C. Croce,et al. MicroRNAs in Cancer. , 2009, Annual review of medicine.
[22] Xin Zheng,et al. RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMP9. , 2015, International journal of oncology.
[23] Jun Yu,et al. CITED2 is a Novel Direct Effector of Peroxisome Proliferator-Activated Receptor Gamma in Suppressing Hepatocellular Carcinoma Cell Growth , 2011 .
[24] Quanyan Liu,et al. The human RNA surveillance factor UPF1 regulates tumorigenesis by targeting Smad7 in hepatocellular carcinoma , 2016, Journal of Experimental & Clinical Cancer Research.
[25] G. A. Ganepola,et al. Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. , 2014, World journal of gastrointestinal oncology.
[26] Jun Yu,et al. Functional role of peroxisome‐proliferator‐activated receptor γ in hepatocellular carcinoma , 2012, Journal of gastroenterology and hepatology.
[27] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.
[28] Meng Xu,et al. Ftx non coding RNA-derived miR-545 promotes cell proliferation by targeting RIG-I in hepatocellular carcinoma , 2016, Oncotarget.
[29] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[30] P. Malfertheiner,et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo , 2006, Hepatology.
[31] Jun Yu,et al. CITED2 is a novel direct effector of peroxisome proliferator‐activated receptor γ in suppressing hepatocellular carcinoma cell growth , 2013, Cancer.
[32] Yingyi Wang,et al. MicroRNA-1468-5p inhibits glioma cell proliferation and induces cell cycle arrest by targeting RRM1. , 2017, American journal of cancer research.
[33] H. Koeffler. Peroxisome proliferator-activated receptor gamma and cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] Gang Liu,et al. A five‐miRNA expression signature predicts survival in hepatocellular carcinoma , 2017, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[35] A. Jemal,et al. Global Cancer Statistics , 2011 .
[36] Wei Yang,et al. MicroRNA-212 suppresses tumor growth of human hepatocellular carcinoma by targeting FOXA1 , 2015, Oncotarget.
[37] Xin Zheng,et al. MicroRNA-130b Promotes Cell Aggressiveness by Inhibiting Peroxisome Proliferator-Activated Receptor Gamma in Human Hepatocellular Carcinoma , 2014, International journal of molecular sciences.
[38] D. Yoon,et al. Peroxisome proliferator-activated receptor-gamma agonist 4-O-methylhonokiol induces apoptosis by triggering the intrinsic apoptosis pathway and inhibiting the PI3K/Akt survival pathway in SiHa human cervical cancer cells. , 2015, Journal of Microbiology and Biotechnology.
[39] C. Grommes,et al. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. , 2004, The Lancet. Oncology.
[40] Miao Sun,et al. MicroRNA and cancer: Current status and prospective , 2006, International journal of cancer.
[41] Takashi Suzuki,et al. CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance , 2016, Cancer science.
[42] Jun Yu,et al. Inhibitory role of peroxisome proliferator‐activated receptor gamma in hepatocarcinogenesis in mice and in vitro , 2010, Hepatology.
[43] C. Azzalin,et al. The Human RNA Surveillance Factor UPF1 Is Required for S Phase Progression and Genome Stability , 2006, Current Biology.
[44] You-cai Zhao,et al. Expression Profiles and Clinical Significance of MicroRNAs in Papillary Renal Cell Carcinoma , 2015, Medicine.
[45] J. Tu,et al. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway , 2017, Molecular Cancer.
[46] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[47] Zhikui Liu,et al. MiR-4319 induced an inhibition of epithelial-mesenchymal transition and prevented cancer stemness of HCC through targeting FOXQ1 , 2019, International journal of biological sciences.
[48] Stephanie Roessler,et al. MicroRNA expression, survival, and response to interferon in liver cancer. , 2009, The New England journal of medicine.